New Imaging Technology Detects Gastric Lymphomas
|
By MedImaging International staff writers Posted on 13 Oct 2021 |
|
Image: MALT lymphomas express the chemokine receptor CXCR4 (Photo courtesy of MedUni)
A new imaging technique for the detection of gastric mucosa-associated lymphoid tissue (MALT) lymphomas could reduce invasive gastroscopy biopsies, according to a new study.
The study, by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), the Medical University of Vienna (MedUni; Austria), and other institutions, explored if [68Ga]Pentixafor, a positron emission tomography (PET) tracer that targets the chemokine receptor CXCR4 (which is overexpressed in MALT lymphoma), could serve as a potential alternative to follow-up biopsies for assessment of residual disease following first-line H. pylori eradication.
The study, which included [68Ga]Pentixafor-PET and magnetic resonance imaging (MRI) scans in 26 gastric MALT lymphoma patients and 20 control group patients without lymphoma, showed that accuracy, sensitivity, specificity, and positive and negative predictive value of [68Ga]Pentixafor-PET for detection of residual gastric MALT lymphoma at follow-up were 97%, 95%, 100%, 100%, and 92.9%, respectively. Maximum and mean PET standardized uptake values also showed correlation with immunohistochemistry-based CXCR4 cell counts. The study was published on September 15, 2021, in Blood.
“Post-treatment evaluation of gastric MALT currently relies on esophagogastroduodenoscopy with histological assessment of biopsies,” concluded lead author Marius Mayerhöfer, PhD, of the MedUni department of biomedical imaging and image-guided therapy, and colleagues. “If a sufficiently high CXCR4 expression is detected at the initial diagnosis of MALT lymphoma, the new imaging could replace repeated gastroscopies in the course of the disease in the future, or at least increase the time intervals between gastroscopies.”
CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1), a molecule with potent chemotactic activity for lymphocytes. After attachment to SDF-1, the CXCR4 protein activates signaling pathways inside the cell that help regulate cell growth and proliferation. CXCR4 is also involved in cell migration cells, especially hematopoietic stem cells in the bone marrow.
Related Links:
Memorial Sloan-Kettering Cancer Center
Medical University of Vienna
 Guided Devices.jpg)
The study, by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), the Medical University of Vienna (MedUni; Austria), and other institutions, explored if [68Ga]Pentixafor, a positron emission tomography (PET) tracer that targets the chemokine receptor CXCR4 (which is overexpressed in MALT lymphoma), could serve as a potential alternative to follow-up biopsies for assessment of residual disease following first-line H. pylori eradication.
The study, which included [68Ga]Pentixafor-PET and magnetic resonance imaging (MRI) scans in 26 gastric MALT lymphoma patients and 20 control group patients without lymphoma, showed that accuracy, sensitivity, specificity, and positive and negative predictive value of [68Ga]Pentixafor-PET for detection of residual gastric MALT lymphoma at follow-up were 97%, 95%, 100%, 100%, and 92.9%, respectively. Maximum and mean PET standardized uptake values also showed correlation with immunohistochemistry-based CXCR4 cell counts. The study was published on September 15, 2021, in Blood.
“Post-treatment evaluation of gastric MALT currently relies on esophagogastroduodenoscopy with histological assessment of biopsies,” concluded lead author Marius Mayerhöfer, PhD, of the MedUni department of biomedical imaging and image-guided therapy, and colleagues. “If a sufficiently high CXCR4 expression is detected at the initial diagnosis of MALT lymphoma, the new imaging could replace repeated gastroscopies in the course of the disease in the future, or at least increase the time intervals between gastroscopies.”
CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1), a molecule with potent chemotactic activity for lymphocytes. After attachment to SDF-1, the CXCR4 protein activates signaling pathways inside the cell that help regulate cell growth and proliferation. CXCR4 is also involved in cell migration cells, especially hematopoietic stem cells in the bone marrow.
Related Links:
Memorial Sloan-Kettering Cancer Center
Medical University of Vienna
Ultrasound Table
Women’s Ultrasound EA Table
Adjustable Mobile Barrier
M-458
New
Radiology Monitor
Barco MDNC-12130 Nio Fusion 12MP Radiology Monitor
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Latest General/Advanced Imaging News
- Virtual Staining Technique Creates Histology Images from CT Data
- CT-Derived Biomarker Predicts Outcomes in Gastric Cancer
- AI Tool Enhances Response Assessment and Survival Prediction in Pleural Mesothelioma
- AI Tool Enables Real-Time Diffuse Optical Tomography for Brain Lesion Detection
- New SPECT/CT Method Differentiates Inflammation from Fibrosis in Interstitial Lung Disease
- Whole-Body PET/CT Tracks Metabolic Changes After Bariatric Surgery
- PET Tracer Localizes Overactive Adrenal Glands in Primary Aldosteronism
- Multimodal AI Tool Combines CT and Health Records to Predict Heart Risk
- AI Tool Automates Radiotherapy Planning for Cervical and Prostate Cancer
- New Proton Therapy Platform Integrates into Existing Radiotherapy Departments
- 3D-Printed Intraoral Device Enhances Head and Neck Radiotherapy Accuracy
- Molecular Imaging Agent Shows Promise for Endometriosis Detection and Monitoring
- Automated AI Tool Detects Early Pancreatic Cancer on Routine CT
- Routine Cardiac CT Enhanced to Predict Heart Failure Risk
- New Breast Imaging Viewer Unifies Modalities and Enhances Clinical Workflow
- Radiomics Analysis of CT Scans Enhances Evaluation of Sarcoidosis
Channels
Radiography
view channel
AI Tool Predicts Five-Year Breast Cancer Risk from Mammograms
Breast cancer risk assessment during routine screening is difficult because many women who develop the disease have no known genetic mutations or family history. Static risk tools provide limited discrimination... Read more
AI Mammography Tools Detect Early Breast Cancer Signs Years Before Diagnosis
Breast cancer screening aims to detect tumors before symptoms develop, but subtle mammographic changes can appear years before diagnosis and may be missed during routine reads. Delayed detection can lead... Read more
MRI
view channel
Cardiac MRI Detects Hidden Heart Dysfunction After Heart Attack
Myocardial infarction often leaves patients with persistent ventricular dysfunction that can progress without obvious signs. Detecting early decline remains difficult because standard measures may miss... Read more
AI Tool Reveals Cortical Lesions on Standard MRI in Multiple Sclerosis
Multiple sclerosis (MS) causes immune-mediated damage in the brain that leads to disability and cognitive decline. Clinicians have long recognized that lesions in the brain’s gray matter, or cortex, are... Read more
Ultrasound
view channel
Simple 2D Ultrasound Tool Accurately Estimates Placental Volume
Stillbirth remains a major cause of perinatal loss, with about 21,000 cases annually in the United States. Although placental abnormalities are linked to adverse pregnancy outcomes, routine monitoring... Read more
Portable 3D Ultrasound System Enables Reproducible Breast Cancer Monitoring
Breast cancer can develop between annual mammograms, and these interval cancers account for 20% to 30% of cases and tend to be more aggressive. The challenge is pronounced in people with dense breast tissue.... Read more
Nuclear Medicine
view channel
Second PSMA PET Identifies Disease in More Than Half of Negative Cases
Biochemical recurrence of prostate cancer after prostatectomy or radiation can be difficult to localize when imaging is negative. Uncertain disease sites may delay salvage therapy and expose patients to... Read more
New PET Tracer Detects DVT and Pulmonary Embolism in One Scan
Deep vein thrombosis is the formation of clots in deep leg veins that can migrate to the lungs as pulmonary embolism. Rapid confirmation across both regions often requires multiple tests and can delay treatment.... Read more![Image: (A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within 7 days. (D) Multimodal imaging evaluation of patient 3, including X-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT. (Photo courtesy of SNMMI)](https://globetechcdn.com/mobile_medicalimaging/images/stories/articles/article_images/2026-06-07/294811110_image_1.jpg "Image: (A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within 7 days. (D) Multimodal imaging evaluation of patient 3, including X-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT. (Photo courtesy of SNMMI)")
Imaging IT
view channel
Ambient AI Reporting Platform Streamlines Radiology Reporting
Radiology departments face growing imaging volumes and staffing shortages, creating reporting bottlenecks and pressure to maintain turnaround times. Conventional dictation tools document findings after... Read more
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
Industry News
view channel
GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare is highlighting Intelligent Radiation Therapy (iRT), MIM Software innovations, and BK Medical surgical... Read more
